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ABSTRACT
Introduction: During the past decade, the volume of
percutaneous coronary intervention (PCI) in China has
risen by more than 20-fold. Yet little is known about
patterns of care and outcomes across hospitals,
regions and time during this period of rising
cardiovascular disease and dynamic change in the
Chinese healthcare system.
Methods and analysis: Using the China PEACE
(Patient-centered Evaluative Assessment of Cardiac
Events) research network, the Retrospective Study of
Coronary Catheterisation and Percutaneous Coronary
Intervention (China PEACE-Retrospective CathPCI
Study) will examine a nationally representative sample
of 11 900 patients who underwent coronary
catheterisation or PCI at 55 Chinese hospitals during
2001, 2006 and 2011. We selected patients and study
sites using a two-stage cluster sampling design with
simple random sampling stratified within economical-
geographical strata. A central coordinating centre
will monitor data quality at the stages of case
ascertainment, medical record abstraction and data
management. We will examine patient characteristics,
diagnostic testing patterns, procedural treatments and
in-hospital outcomes, including death, complications of
treatment and costs of hospitalisation. We will
additionally characterise variation in treatments and
outcomes by patient characteristics, hospital, region
and study year.
Ethics and dissemination: The China PEACE
collaboration is designed to translate research into
improved care for patients. The study protocol was
approved by the central ethics committee at the China
National Center for Cardiovascular Diseases (NCCD)
and collaborating hospitals. Findings will be shared
with participating hospitals, policymakers and the
academic community to promote quality
monitoring, quality improvement and the efficient
allocation and use of coronary catheterisation and PCI
in China.
Registration details: http://www.clinicaltrials.gov
(NCT01624896).
INTRODUCTION
China, a country with a rapidly rising preva-
lence of cardiovascular disease,
1–3 is con-
comitantly expanding access to advanced
cardiovascular procedures. During the past
decade, the volume of percutaneous coron-
ary intervention (PCI) has increased more
than 20-fold.
45This expansion has occurred
in the context of rising rates of health insur-
ance coverage and healthcare costs.
67The
optimal deployment of advanced care strat-
egies in settings of constrained resources is a
common challenge faced by many low-
income and middle-income countries.
8
Although the overall volume of coronary
catheterisation and PCI procedures per-
formed in China is known,
9–12 there are gaps
in knowledge about the details of their use
and associated outcomes. Nationally repre-
sentative data are lacking, and studies have
generally included only a small number of
Strengths and limitations of this study
▪ Hospitalisations were sampled from a nationally
representative hospital network for the years 2001,
2006 and 2011 to examine the influence of major
changes in the Chinese healthcare system and the
creation of percutaneous coronary intervention
(PCI) guidelines by Chinese medical societies.
▪ To elevate the quality of abstracted data, the
study uses data collection techniques regularly
employed by international clinical trials such as
integrated central and on-site monitoring as well
as source document checking.
▪ Findings will be shared with hospitals and pol-
icymakers to improve healthcare quality.
▪ Patient outcomes are limited to in-hospital out-
comes, and data collection is limited to informa-
tion available in medical records.
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time periods.
51 3 –15 Longitudinal data on coronary cath-
eterisation and PCI have largely been derived from a
single centre.
16 We therefore know relatively little about
patient selection, use of speciﬁc procedural technologies
and adjunctive therapies, and patient outcomes, includ-
ing their variation over time and by site of care. We
know even less about the inﬂuence of major Chinese
health reforms and evolving standards for accreditation
of physicians and hospitals that perform coronary cath-
eterisation and PCI.
17
To address these gaps in knowledge and as a prelude to
national quality improvement efforts, we have leveraged
the China PEACE (Patient-centered Evaluative Assessment
of Cardiac Events) research network to perform the China
PEACE Retrospective Study of Coronary Catheterisation
and Percutaneous Coronary Intervention (China
PEACE-Retrospective CathPCI Study). China PEACE is a
collaborative effort among the China National Center for
Cardiovascular Diseases (NCCD); the Yale-New Haven
Hospital Center for Outcomes Research and Evaluation;
the Chinese government; and a national network of
Chinese hospitals (ﬁgure 1). The goal of the network is to
generate new knowledge relevant to practice and policy
and to translate this knowledge into action to improve care
and outcomes for patients with cardiovascular disease.
The China PEACE-Retrospective CathPCI Study will
examine a nationally representative sample of almost
12 000 patients who underwent coronary catheterisation or
PCI from 55 Chinese hospitals during 2001, 2006 and 2011.
This approach will permit the study of care patterns and
outcomes across hospitals, regions and time during a
dynamic period of healthcare reform. The study is largely
descriptive, and rather than test a speciﬁch y p o t h e s i s ,
seeks to provide a foundation for future quality improve-
ment and research. Speciﬁc aims of the China
PEACE-Retrospective CathPCI Study are: (1) to describe
the characteristics of patients undergoing coronary cath-
eterisation or PCI in China including their demographic,
socioeconomic and clinical attributes; (2) to characterise
patterns of treatment including the use of procedural tech-
nologies and adjunctive therapies; (3) to describe
in-hospital outcomes such as mortality, treatment complica-
tions, length of stay and hospital charges; (4) to characterise
differences in treatment and outcomes by patient character-
istics, hospital, region and year of study and (5) to examine
adherence to quality measures for PCI. Research ﬁndings
will be shared with study hospitals and the Chinese govern-
ment to improve the selection of patients for these proce-
dures and their associated outcomes. In this paper, we
describe study methodology, abstracted data elements,
planned statistical analyses and initial enrolment of sites.
METHODS AND ANALYSIS
Design overview
We deﬁned our study cohort based only on in-hospital
coronary catheterisations, as these procedures are not
commonly performed on an outpatient basis in China.
We included patients undergoing coronary catheterisa-
tion for any indication. We sampled eligible hospitalisa-
tions for 2001, 2006 and 2011 from a network of
nationally representative hospitals. We chose these three
time periods to reﬂect the inﬂuence of major changes
in the Chinese healthcare system and the creation of
PCI guidelines by Chinese medical societies (ﬁgure 2).
Figure 1 The China PEACE
initiative. Key partners include the
Chinese government,
collaborating hospitals, the China
National Center for
Cardiovascular Diseases and the
Yale-New Haven Hospital Center
for Outcomes Research and
Evaluation. The China
PEACE-Retrospective CathPCI
Study is one of five initial studies
from the China PEACE initiative.
The topic areas for these five
projects concern acute
myocardial infarction, coronary
catheterisation/percutaneous
coronary intervention and
multivessel coronary artery
disease. Future studies will focus
on cerebrovascular disease and
other cardiovascular conditions.
3VD, triple-vessel coronary artery
disease; AMI, acute myocardial
infarction; PCI, percutaneous
coronary intervention.
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ment patterns and outcomes nationally and within
regions of different socioeconomic development, we
drew a representative, stratiﬁed sample of patient dis-
charges for each year. We intentionally drew a larger
sample for 2011 to obtain more precise estimates of the
current performance and variation in treatment patterns
and outcomes among hospitals.
The central ethics committee at the China NCCD
approved the China PEACE-Retrospective CathPCI Study.
All collaborating hospitals accepted the central ethics
approval except for ﬁve hospitals, which obtained local
approval by internal ethics committees. The study is regis-
tered at http://www.clinicaltrials.gov (NCT01624896).
The Chinese government, which provided ﬁnancial
support for the study, had no role in its design or
conduct; in the collection, management, analysis and
interpretation of the data; or in the preparation or
approval of the manuscript.
Sampling design
We chose hospitals to reﬂect the diverse sites of care that
perform coronary catheterisation and PCI. Candidate hos-
pitals were limited to urban areas, as catheterisation cap-
ability is restricted almost exclusively to these regions. We
identiﬁed urban areas using ofﬁcial administrative divi-
sions, in which a region is considered urban if it is part of
a downtown or suburban area within a direct-controlled
municipality (Beijing, Tianjin, Shanghai and Chongqing)
or 1 of 283 prefectural-level cities. In total, Mainland
China is composed of 287 urban regions. As ﬁnancial and
medical resources are not identical throughout Mainland
China, we separately identiﬁed hospitals in each of its
three ofﬁcial economical-geographical regions, that is,
Eastern, Central and Western. As Central and Western
urban regions have similar per capita income and health
services capacity, we combined Central and Western
regions into one stratum.
18 We then identiﬁed hospitals
separately for two study strata: Eastern-urban and Central/
Western-urban.
We identiﬁed cases for study inclusion using a stratiﬁed
two-stage cluster sampling design (ﬁgure 3). In the ﬁrst
stage, we identiﬁed hospitals using a simple random sam-
pling procedure in each stratum. The sampling frame-
work consisted of the highest-level hospitals in each of
the predeﬁned urban regions with the potential capabil-
ity of performing PCI (833 hospitals in 287 urban
regions). Hospital level is ofﬁcially deﬁned by the
Chinese government based on clinical resource capacity,
for example, secondary hospitals have at least 100
inpatient beds and the capacity to provide acute medical
care and preventive care services to populations of at
least 100 000, while tertiary hospitals are large referral
centres in provincial capitals and major cities.
15 19 We
excluded military hospitals, prison hospitals, specialised
hospitals without a cardiovascular disease division, and
traditional Chinese medicine hospitals. We selected rep-
resentative hospitals from 2011 to reﬂect current prac-
tices and traced this same hospital cohort backwards to
2006 and 2001 to describe temporal trends. As hospital
numbers have grown by approximately 18% over the past
decade,
20 21 the cohort should be most representative of
national treatment patterns and outcomes in 2011.
In the second stage, we drew cases based on the local
hospital database for patients who underwent coronary
catheterisation or PCI at each sampled hospital using sys-
tematic random sampling procedures. For each stratum,
we determined the sample size required to achieve a
1.5% precision for describing the percentage of patients
experiencing in-hospital complications, which we
Figure 2 Chinese trends in PCI
volume from 2001 to 2011.
Figure demonstrates the increase
in PCI volume by year and the
increase in the number of
hospitals performing >100 PCIs
per year. Notable events pertinent
to the expansion in PCI access
with time are highlighted below
the graph. In 2003, the Rural
Cooperative Medical Care System
expanded health insurance to
low-income rural residents. The
healthcare reform of 2007
substantially expanded health
spending for the rural and urban
population. We sampled eligible
hospitalisations for 2001, 2006
and 2011. PCI, percutaneous
coronary intervention.
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92 2 –25 To achieve a precision of 1.5%
with an α of 0.05 in each stratum, assuming an intraclass
correlation of 0.02 and design effect of 2.2, we would
need to sample 1750 records among hospitals with an
average cluster size of 60. This cluster size appeared rea-
sonable based on national administrative data
26 and our
previous survey of treatment for acute coronary syn-
dromes at more than 1000 hospitals in 2010, which
demonstrated that the median annual PCI volume was
approximately 300 cases. Assuming a participation rate
of 85% among selected hospitals, we approached 35 hos-
pitals for participation in each stratum, for a total of 70
hospitals. We doubled cluster sizes for 2011 to improve
precision in the description of hospital-level treatment
patterns and outcomes. Consequently, the total expected
sample volume with the above assumptions was approxi-
mately 3500 cases in 2001, 3500 cases in 2006 and 7000
cases in 2011. A more detailed description of the sam-
pling strategy is provided in the supplemental material
within the online web appendix.
Data collection
We trained staff at participating hospitals to identify all
hospitalisations with coronary catheterisation or PCI pro-
cedures from their respective local hospital databases for
2001, 2006 and 2011. After we sampled cases at each
hospital, we assigned each case a unique study ID. We
then required local investigators to obtain the original
record and transmit a scanned copy to the coordinating
centre. To facilitate this process, the coordinating centre
provided each study site with a high-speed scanner. To
verify compliance with the case-ﬁnding strategy, research
staff from the coordinating centre visited 60% of the
sites to repeat the case-ﬁnding process, conﬁrm that the
Figure 3 The China
PEACE-Retrospective CathPCI
Study flow chart and associated
quality assurance strategies. The
flow chart should be read from
top to bottom. CRF, case report
form; Q & A, questions and
answers.
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tion or PCI was complete, and assist in acquiring the
sampled cases (ﬁgure 3). We chose to visit study sites
that were expected to contribute a large volume of cases
and have potential difﬁculties in complying with the
case-ﬁnding strategy. These sites provided 73% of
sampled cases.
Following receipt of the scanned record, research staff at
the China NCCD ensured the completeness and quality
with which each medical record was copied. We required
incomplete or poorly scanned records to be rescanned
and retransmitted (ﬁgure 3). We instructed study sites to
include all parts of the medical record, including the face
sheet, admission note, daily progress notes, procedure
notes, medication administration record, diagnostic pro-
cedure reports, laboratory test results, physician orders,
nursing notes and discharge summary.
The China PEACE-Retrospective CathPCI Study
adhered to rigorous standards for abstraction. Before initi-
ating the chart review, each abstractor received 2 weeks of
training that included an introduction to the study, coron-
ary heart disease and its subtypes, components of the
inpatient medical record including specialised sections
such as catheterisation reports, and the China
PEACE-Retrospective CathPCI Study data dictionary. We
provided all material, including the data dictionary, in
Chinese. After training, we certiﬁed individuals who were
able to abstract ﬁve sample medical records with greater
than 98% accuracy. Inexperienced abstractors began with
exclusively typewritten rather than handwritten medical
records. In addition, we randomly audited approximately
5% of the abstracted records. If the records were not
abstracted with 98% accuracy, all medical records in the
audited batch were considered unqualiﬁed and were
re-reviewed by a different abstractor. Abstractors were
required to maintain this benchmark of 98% accuracy to
retain certiﬁcation. We used abstractors with formal
medical training to identify data elements requiring more
advanced medical knowledge, such as the development of
postprocedural complications including bleeding or
cardiac tamponade. A physician was always present in the
room with abstractors or was available online to answer
questions as they arose. We assigned medical records
belonging to the same hospital and year to a broad group
of reviewers to avoid potential residual disparities in
quality among abstractors.
Data management
We systematically perform ongoing data cleaning. Data
managers regularly query data for invalid and illogical
values as well as for duplicate record entries. They iden-
tify potential invalid values by searching for outliers in
continuous data distributions. Records with identical
study identiﬁcation numbers, hospital identiﬁcation
numbers, medical record identiﬁcation numbers and
dates of discharge trigger a search for duplicate records.
Once a data query is made, concerns are resolved after
tracing and reviewing the relevant records.
All data have been treated as protected health infor-
mation and are thus securely stored in an encrypted and
password protected database at the main coordinating
centre.
Data elements
We examined the English language and Chinese literature
for relevant studies to create a list of candidate variables.
We supplemented these elements with variables used in
the CathPCI Registry of the American College of
Cardiology National Cardiovascular Data Registry (NCDR).
CathPCI is an outcome-based registry and quality improve-
ment programme that focuses on patients who undergo
coronary catheterisation and PCI in the USA.
Incorporating variables from CathPCI will permit cross-
country comparisons in resource utilisation and adherence
to quality metrics. We also incorporated elements from the
case report form used in the China PEACE Retrospective
Study of Acute Myocardial Infarction
27 (clinicaltrials.gov
identiﬁer NCT01624883) to permit comparison of hospita-
lisations for acute myocardial infarction between these two
China PEACE studies. Major categories of data elements
are described in table 1.
In table 2, we show data relevant to performance mea-
sures during the ﬁrst 24 h of hospitalisation and at hos-
pital discharge for patients with acute myocardial
infarction and those undergoing PCI for stable coronary
artery disease.
Where possible, we collected data that would allow us to
construct the core quality measures for acute myocardial
infarction used and reported by the Centers for Medicare
& Medicaid Services in the USA as well as the quality mea-
sures for PCI from the NCDR.
28 Two physician investiga-
tors at each participating hospital also completed a survey,
modelled on the annual survey of hospitals performed by
the American Hospital Association, of its major structural
and organisational characteristics during the study
period.
29 Key variables assessed include bed size, teaching
status and capability of performing coronary artery bypass
graft surgery.
Statistical analyses
We will report summary statistics for patient character-
istics, use of diagnostic tests, treatments received and
in-hospital outcomes, including complications of care
and hospitalisation costs across study sites. Weighting will
reﬂect the reciprocal of sampling probability. For each
aim, we will use standard parametric and non-parametric
techniques for observational data, including t tests, χ
2
tests, Wilcoxon rank sum tests and generalised linear
models. Because patient characteristics, treatments and
outcomes may be correlated within hospitals, analyses
will account for the effect of clustering. To examine and
adjust for differences between comparison groups, we
will use linear, logistic, Cox proportional hazard and
Poisson models with a generalised estimating equation
approach and hierarchical models, where appropriate.
We will develop models to stratify patients according to
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tionship of candidate variables to in-hospital outcomes
using appropriate statistical techniques for the depend-
ent variable. We will further reﬁne the list of candidate
variables based on their clinical relevance.
Progress to date
As of December 2012, 55 hospitals agreed to participate
in the study. Fifteen hospitals did not participate
because they did not provide inpatient services for cor-
onary heart disease (5 hospitals), were incapable of per-
forming coronary catheterisation and PCI throughout
the study period (8 hospitals), or refused to participate
(2 hospitals). Of the 55 participating hospitals, 29 were
located in the Eastern economical-geographical stratum
and 26 were located in the Central/Western economical-
geographical stratum. The distribution of sites by prov-
ince and region is shown in ﬁgure 4.
In parallel with national trends, the number of hospi-
tals providing cases increased with each subsequent year
of study. In 2001, 26 of the 55 participating hospitals
were capable of performing PCI, of which 24 submitted
medical records. Of the two hospitals that did not
submit records, one did not keep records in 2001 and
the other had its records destroyed by a ﬁre. Both of
these institutions most likely had a very limited capacity
for PCI in 2001, as evidenced by their performance of
only 16 and 28 respective cases of coronary catheterisa-
tion or PCI in 2006. A total of 44 hospitals performed
PCI in 2006, all of which submitted records to the study.
Table 2 China PEACE-Retrospective CathPCI Study
performance measures
First 24 h Discharge
Aspirin Aspirin*
Time to primary
PCI
Thienopyridine*
Time to
fibrinolysis
β blocker
ACE inhibitor or ARB for LV systolic
dysfunction
Statin*
Smoking cessation counselling
Cardiac rehabilitation referral
All performance measures apply to patients with acute myocardial
infarction. Performance measures with asterisks also apply to
patients undergoing PCI for stable coronary artery disease.
ARB, angiotensin receptor blocker; LV, left ventricle; PCI,
percutaneous coronary intervention.
Table 1 China PEACE-Retrospective CathPCI Study data elements
Category Example elements
Patient demographics Age, sex, ethnicity, postal code, occupation and insurance status
Medical history Diabetes, hypertension, hyperlipidaemia, vascular disease and prior revascularisation
Initial cardiac status Heart rate, blood pressure, Killip class, heart failure and cardiac arrest
Lab values Troponin, CK, CK-MB, BNP, sodium, BUN, creatinine, WBC count and haemoglobin
Diagnostic procedures Coronary catheterisation, echocardiogram, CT angiogram, stress testing and chest
radiograph
Medications including dose Antiplatelet therapy, anticoagulant therapy, beta blocker, ACE inhibitor/ARB, statin, and
traditional Chinese medicines
Auxiliary imaging Intravascular ultrasound and fractionated-flow reserve
Coronary flow dynamics Preprocedural TIMI flow and postprocedural TIMI flow
Revascularisation Fibrinolysis, PCI (access, coronary anatomy, bypass graft anatomy, stent number, stent
type, stent length, contrast dose and closure device) and CABG surgery
Mechanical support Intra-aortic balloon pump, left ventricular assist device and ECMO
Outcomes including in-hospital
complications
Death, myocardial infarction, heart failure, shock, arrhythmia, stroke, bleeding,
transfusion, infection, coronary perforation and coronary dissection
ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CK,
creatine kinase; ECMO, extracorporeal membrane oxygenation; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial
infarction; WBC, white blood cell.
Figure 4 Geographical distribution of participating hospitals
in the China PEACE-Retrospective CathPCI Study. Of the 70
sampled hospitals, 15 were unable or unwilling to participate
and 55 provided cases for the study.
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2011. As with 2006, all hospitals that performed PCI in
2011 submitted records.
We collected all medical records for abstraction by
December 2012. The examination of census databases
from participating hospitals yielded 58 008 hospitalisa-
tions for coronary catheterisation and PCI (3270 in 2001,
12 875 in 2006 and 41 863 in 2011). Of these 58 008 hos-
pitalisations, we sampled 12 477 (22%; 1444 (44%) in
2001, 3046 (24%) in 2006 and 7987 (19%) in 2011). Of
these 12 477 sampled hospitalisations, we acquired
medical records for 11 900 (95%); 577 (5%) medical
records could not be found due to poor archiving. We
began data abstraction of these medical records in March
2013 and expect abstraction to be completed in January
2014.
DISCUSSION
Through the use of a national research network, the
China PEACE-Retrospective CathPCI Study is developing
a repository of data that describes the current and former
use of coronary catheterisation and PCI in China. This
project will provide answers to questions about contem-
porary practice patterns including variation among insti-
tutions and temporal trends in procedure use and
adjunctive therapy. To elevate the quality of abstracted
data, the study uses data collection techniques regularly
employed by international clinical trials such as inte-
grated central and on-site monitoring as well as source
document checking. The China PEACE-Retrospective
CathPCI Study also elicits the active participation of hos-
pitals across China to ensure that study results dissemin-
ate broadly for the purpose of quality improvement.
Findings will be shared with government to help research
ﬁndings inform policy. The study is designed to guide the
efﬁcient allocation and high-quality use of advanced car-
diovascular interventions in the context of a rapidly
growing cardiovascular disease burden and dynamically
changing healthcare system.
The China PEACE-Retrospective CathPCI Study falls
under the larger China PEACE effort, which aims to
create a national research network dedicated to improv-
ing cardiovascular outcomes. China PEACE is built on a
platform of collaboration and coordination between
clinicians, researchers and policymakers. With this
framework in mind, study sites do not merely transmit
information to the coordinating centre, but are full part-
ners and consumers of the knowledge generated. In this
way, China PEACE has similarities to the NCDR CathPCI
Registry of the American College of Cardiology, which
provides participating hospitals with regular perform-
ance reports, including analysis of process measures and
in-hospital outcomes.
The Chinese government, a partner in China PEACE,
will use study results to develop policies intended to
strengthen the clinical performance of the hospitals.
The goal is not simply to identify poor performing
institutions, but to use a shared learning approach to
elevate care delivery at all participating hospitals and
produce knowledge that is broadly applicable across sites
of care, including those external to the China PEACE
network. In the future, we hope to directly involve
patients and caregivers in designing study questions and
disseminating ﬁndings.
We anticipate that the results of the China
PEACE-Retrospective CathPCI study will illuminate the
effects of recent healthcare reforms in China on the use
of coronary catheterisation and PCI. Although China has
adopted policies to enhance quality of care and dissemin-
ation of novel technologies over the past decades,
17 they
have been applied differentially across the country.
26
After the ﬁrst PCI was performed in China in 1985,
5
there followed a period of unregulated dissemination.
30 31
In 2000, most patients paid for PCI themselves, and there
was widespread variation in access to the technology.
67
Access was subsequently improved in 2003 with the imple-
mentation of the Rural Cooperative Medical Care
Scheme that expanded insurance access to the low-
income rural population. This government initiative was
followed by additional healthcare reforms in the latter
half of the decade that further expanded insurance
support for rural and urban residents.
67In this context,
the Ministry of Health established processes for accredit-
ation of interventional centres in 2007 to promote
minimal quality standards for PCI.
17 Through our nation-
ally representative and multiyear sample of catheterisa-
tion and PCI, we will have the capacity to evaluate the
temporal inﬂuence of these policies on practice patterns
and their variability by hospital and region. We may iden-
tify signals of potentially inefﬁcient allocation of
resources such as the use of drug-eluting stents in situa-
tions where bare-metal stents are similarly efﬁcacious.
Results may prove useful to future policymaking and
guideline development.
We also expect that the knowledge generated from the
China PEACE-Retrospective CathPCI Study will be useful
internationally. Many low-income and middle-income
countries are undergoing a similar epidemiological transi-
tion and experiencing comparable challenges associated
with a growing number of persons with chronic cardiovas-
cular disease and rapidly rising healthcare costs in the
setting of limited healthcare resources.
32 The experience
with China PEACE may help guide other countries in
their desire to learn about trajectories and variation in the
use of novel health technologies. Developed nations are
also facing common challenges around healthcare reform
and the optimal utilisation of advanced interventions.
33
The development of novel approaches to care in China
may have relevance for more wealthy countries that are
grappling with escalating costs and trying to determine
whether reduction in resource expenditures can be
achieved without compromising patient outcomes.
The China PEACE-Retrospective CathPCI Study is dis-
tinguished from many retrospective analyses by its use of
data quality control strategies that are common in the
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devoted signiﬁcant attention to data quality at multiple
stages, including case ascertainment, data abstraction
and data management. For example, research staff
visited study sites to identify all hospitalisations involving
coronary catheterisation or PCI from local hospital data-
bases and physically found all medical records for
sampled cases whenever possible. In addition, all abstrac-
tors underwent standardised training at the coordinating
centre and continued to maintain high standards for
accuracy to remain certiﬁed. Medical records reviewed
by abstractors who fail to meet continuing recertiﬁcation
requirements are always reabstracted. These and other
quality control and assurance strategies are the result of
the NCCD’s previous experience in conducting cardio-
vascular clinical trials in China.
This study has some limitations, including those inher-
ent to its retrospective design. Findings depend on the
accuracy and completeness of the medical records, and
the abstraction process. However, these limitations would
apply to all retrospective studies. Moreover, the identiﬁca-
tion of poor documentation of key variables is crucial to
future quality improvement measurements. Our study is
not designed to track outcomes following hospitalisation
or the experience of patients. These variables, however,
will be collected in the recently launched Prospective
Study of PCI from the China PEACE platform. Finally, in
our sampled hospital cohort, catheterisation and PCI
volume were smaller than expected for the year 2001, in
particular, as the number of hospitals capable of perform-
ing PCI and the PCI volume per centre were relatively
low. However, the sample remains nationally representa-
tive in the last year and can still provide acceptable preci-
sion in describing 10-year trends (supplemental material
within the online web appendix).
The China PEACE-Retrospective CathPCI Study, one of
the ﬁrst studies to be launched from the China PEACE
platform, seeks to assess the characteristics, treatments
and outcomes of patients who receive diagnostic catheter-
isation and PCI in a large, nationally representative
sample of hospitals in China. It provides a unique oppor-
tunity to compare variation in care and to assess trajector-
ies in practice in the context of an era of rapid adoption
of new cardiovascular technologies and constrained
healthcare resources. Findings are intended to guide the
more efﬁcient use of coronary catheterisation and PCI in
a manner that improves health outcomes across diverse
geographical settings and sites of care within China.
Dissemination
The Chinese government, which provided ﬁnancial
support for the study, had no role in its design or
conduct; in the collection, management, analysis and
interpretation of the data; or in the preparation or
approval of this manuscript.
Study ﬁndings will be shared freely with participating
hospitals and the Chinese government. To improve
healthcare quality, data will be presented in the format
of regular performance reports that include analysis of
process measures and in-hospital outcomes. Findings
will also be disseminated via peer-reviewed publications.
Requests for collaboration will be welcomed.
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